Cleveland, OHNCT03378102Now EnrollingIRB Ready

Allogeneic Hematopoietic Stem Cell Transplantation Clinical Trial in Cleveland, OH

Access cutting-edge allogeneic hematopoietic stem cell transplantation treatment through this clinical trial at a research site in Cleveland. Study-provided care at no cost to qualified participants.

Sponsored by Mari Dallas

Quick Self-Assessment

See if you qualify for this Cleveland location

Preparing your pre-screening questions…

Expert Care in Cleveland

Access allogeneic hematopoietic stem cell transplantation specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related allogeneic hematopoietic stem cell transplantation treatment provided free

Apply for This Cleveland Location

Check if you qualify for this allogeneic hematopoietic stem cell transplantation clinical trial in Cleveland, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Cleveland

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Cleveland site if eligible
  4. 4Begin participation

About This Allogeneic Hematopoietic Stem Cell Transplantation Study in Cleveland

The purpose of this study is to determine if it is possible to treat an infection with a cell-based immunotherapy (therapy that uses the patient's own immune system to treat the infection). This treatment is called adoptive T cell therapy. Another purpose is to learn about the side effects and toxicities of adoptive T cell therapy. Adoptive T cell therapy is an investigational (experimental) therapy that works by using the blood of a donor that has immunity against the virus. The donor cells are collected and then the cells, called T cells, that are capable of defending against the virus are selected out. These selected T cells are then infused back into the patient, to try to give the immune system the ability to fight the infection. Adoptive T cell therapy is experimental because it is not approved by the Food and Drug Administration (FDA).

Sponsor: Mari Dallas

Who Can Participate

Inclusion Criteria

Patients must have received allogeneic HSCT and be greater than 30 days post-HSCT at the time of registration.
Patients must have evidence of documented HAdV infection/reactivation. Patients may be:
Symptomatic with any detectable viral load OR
Asymptomatic with viral load that is: \>1000 copies/ml in peripheral blood OR qualitative detection in stool, urine and/or other specimens
Patients must have poor response and/or contraindication to therapy:
Absence of an improvement of viral load (decrease by at least 1 log, i.e. 10-fold) after ≥ 14 days of antiviral therapy with ganciclovir, valganciclovir and/or foscarnet. OR
New, persistent and/or worsening HAdV-related symptoms, signs and/or markers of end organ compromise while on antiviral therapy with ganciclovir, valganciclovir or foscarnet. OR
Have contraindications or experience adverse effects of antiviral therapy with ganciclovir, valganciclovir, cidofovir or foscarnet.
Performance Score: Eastern Cooperative Oncology Group (ECOG) Performance Score ≤ 3. Karnofsky (≥ 16 years) or Lansky (\<16 years) performance score ≥ 50
The effects of virus-specific, antigen-selected T cells on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 4 weeks prior to study entry, for the duration of study participation and for 3 months after completing treatment.
Subjects who are 14 years and older must have the ability to understand and the willingness to sign a written informed consent document, or assent document.

Exclusion Criteria

Pregnant or breastfeeding women are excluded from this study. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with the agents described above, breastfeeding should be discontinued if the mother participates in this trial.
Patients with opportunistic viral infections other than HAdV.
Patients with active, grade II-IV, acute graft versus host disease (GVHD), chronic GVHD or any condition requiring high doses of glucocorticosteroid (\>0.5 mg/kg/day prednisone or its equivalent) as treatment.
Treatment with antithymocyte globulin within 28 days of planned infusion of virus - specific, antigen selected T cells.
Treatment with virus - specific T cells within 6 weeks (42 days) of planned infusion.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cleveland?

Yes, this clinical trial (NCT03378102) has an active research site in Cleveland, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Allogeneic Hematopoietic Stem Cell Transplantation Treatment Options in Cleveland, OH

If you're searching for allogeneic hematopoietic stem cell transplantation treatment options in Cleveland, OH, this clinical trial (NCT03378102) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cleveland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced allogeneic hematopoietic stem cell transplantation specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all allogeneic hematopoietic stem cell transplantation clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Cleveland, OH

See all leukemia clinical trials recruiting in Cleveland — not just this study.

Browse Leukemia Trials in Cleveland →

Browse More Trials by Condition

Leukemia TrialsEssential Tremor TrialsRheumatoid Arthritis TrialsInterstitial Cystitis TrialsOrgan Transplant TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Cleveland?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Cleveland, OH